Differences and clinical application analysis between mobosetinib (Anvili) and mobosetinib

Mobocertinib (trade name: Exkivity), also known as mobocertinib, is a different translation or market name of the same drug. It is an oral small molecule targeted drug specifically developed for patients with non-small cell lung cancer (NSCLC) with insertion mutations in EGFR Ex20ins. As a precision targeted drug, mobosetinib inhibits tumor cell proliferation and survival by blocking the abnormally activated EGFR signaling pathway.

“Mobosetinib” is mainly used in international or Chinese literature, while “Mobosetinib” is a simplified translation or commercial name commonly used in China. The two are completely identical in terms of drug ingredients, dosage forms, dosages and mechanisms of action, so patients, doctors or researchers do not need to be confused when encountering different names in the literature. Understanding its uniformity can help standardize medication use and information access.

Mobosetinib is mainly used for patients with EGFR Ex20insmutationsNSCLC who have progressed after previous standard treatment. Clinical studies have shown that the drug has significant anti-tumor activity in this type of patients, including an objective response rate of approximately 28%-30% and a median progression-free survival of approximately 7 months. Compared with traditional chemotherapy, mobosetinib can provide a more precise treatment option, especially for patients who are insensitive to conventional EGFR inhibitors.

Mobosetinib, as a targeted drug for EGFR Ex20ins mutations, provides new hope for patients who previously lacked effective treatments. In the future, with the popularization of molecular testing and the accumulation of more clinical trial data, the application of this drug is expected to be further expanded in early treatment, combination regimens, and different populations. In addition, clarifying the uniformity of their names helps doctors accurately prescribe medications and educate patients in clinical practice.

Reference link:https://www.drugs.com

xa0